13F-HR: Gilead Sciences Q1 2026 13F Holdings Disclosure

Gilead Sciences reports $2.12 billion in equity holdings across six biotechnology investments as of March 31, 2026.

Summary

• Gilead Sciences filed its Form 13F for the quarter ended March 31, 2026.
• The total value of reported equity holdings is approximately $2.12 billion.
• The portfolio consists of six specific biotechnology and pharmaceutical equity positions.
• Major holdings include Arcellx Inc ($771.7M) and Arcus Biosciences Inc ($678.8M).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure of existing investment positions with no new strategic shifts indicated.

Positives

• Maintains significant strategic stakes in key biotechnology partners.
• Demonstrates continued investment in clinical-stage innovation through equity holdings.

Negatives

• Portfolio is highly concentrated in a small number of biotech equities, increasing exposure to sector-specific volatility.

Risks

• Market value of holdings is subject to fluctuations in the biotech sector.
• Concentration risk in specific clinical-stage companies.

Future Outlook

The filing does not provide forward-looking guidance, as it is a retrospective disclosure of equity holdings.

Industry Context

StockSavvy.ai notes that Gilead Sciences continues to utilize its balance sheet to maintain strategic equity positions in its R&D partners, a common practice for large-cap biopharma firms looking to secure pipeline access.

Comparison to Industry Standards

• Consistent with the investment strategies of large-cap pharmaceutical peers like Pfizer or Novartis, which often hold minority stakes in smaller biotech innovators.
• The portfolio reflects a focus on oncology and immunology, aligning with broader industry trends toward targeted therapies.

Stakeholder Impact

• Shareholders gain transparency into the company's strategic equity investments.
• Partner companies (Arcellx, Arcus, etc.) benefit from the continued institutional backing of Gilead.

Next Steps

• Future 13F filings will be required on a quarterly basis to update equity positions.

Key Dates

Keywords

Gilead Sciences, 13F, Biotechnology, Equity Holdings, Investment Portfolio, Arcellx, Arcus Biosciences